InnFocus gets financing FDA authorization for MicroShunt study

The U.S. Food and Drug Administration has granted authorization to InnFocus to begin a phase 1 trial of its MicroShunt device to treat open-angle glaucoma, according to a news release.InnFocus also received $13.4 million in financing from HOYA Group and Saints Capital Everest, the release said.

Full Story →